Established in 2013 by Professor Tore Bengtsson and supported by private investors, Atrogi prioritizes tangible outcomes. Bolstered by a team of leading experts, we are committed to navigating the complex journey of clinical development and market introduction. Our primary objective is to enhance the management of type 2 diabetes by creating a transformative drug. Leveraging our extensive expertise in clinical research and bus...
Established in 2013 by Professor Tore Bengtsson and supported by private investors, Atrogi prioritizes tangible outcomes. Bolstered by a team of leading experts, we are committed to navigating the complex journey of clinical development and market introduction. Our primary objective is to enhance the management of type 2 diabetes by creating a transformative drug. Leveraging our extensive expertise in clinical research and business development, Atrogi is poised to successfully launch this innovative treatment globally.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.